Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Revenue: 2010-2025

Historic Revenue for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $256.5 million.

  • Arrowhead Pharmaceuticals' Revenue rose 1851.02% to $256.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $829.4 million, marking a year-over-year increase of 3639.51%. This contributed to the annual value of $829.4 million for FY2025, which is 23258.15% up from last year.
  • As of Q3 2025, Arrowhead Pharmaceuticals' Revenue stood at $256.5 million, which was up 823.66% from $27.8 million recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' 5-year Revenue high stood at $542.7 million for Q1 2025, and its period low was -$14.6 million during Q3 2024.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median Revenue value was $15.8 million (recorded in 2023), while the average stood at $89.5 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' Revenue tumbled by 190.99% in 2024 and then soared by 7,591.84% in 2025.
  • Arrowhead Pharmaceuticals' Revenue (Quarterly) stood at $27.4 million in 2021, then surged by 127.95% to $62.5 million in 2022, then crashed by 94.32% to $3.6 million in 2023, then decreased by 29.60% to $2.5 million in 2024, then spiked by 1,851.02% to $256.5 million in 2025.
  • Its Revenue stands at $256.5 million for Q3 2025, versus $27.8 million for Q2 2025 and $542.7 million for Q1 2025.